Marked exacerbation of resolving macrophage activation syndrome in a patient with adult-onset Still's disease following one dose of granulocyte colony-stimulating factor

Alana Petrassi, Connor Buechler, Priyanjali Pulipati, Elie Gertner

Research output: Contribution to journalArticlepeer-review

Abstract

Macrophage activation syndrome (MAS) is a frequent complication of adult-onset Still's disease (AOSD) and is characterised by organ dysfunction, cytopenia and coagulopathy. There are few data regarding the use of granulocyte colony-stimulating factor (G-CSF) as a treatment for neutropenia in MAS due to AOSD. This case describes a previously healthy mid-20s patient who was diagnosed with AOSD and subsequently MAS. Although his clinical symptoms and ferritin levels responded well to steroids, interleukin-1 inhibition and Janus kinase inhibition, he developed prolonged and profound neutropenia for which he received one dose of G-CSF. His MAS flared markedly, requiring intensive immunosuppression and significantly prolonging his hospital stay. This report illustrates that G-CSF carries the risk of worsening inflammation leading to MAS, particularly in auto-inflammatory conditions such as AOSD.

Original languageEnglish (US)
Article numbere262024
JournalBMJ case reports
Volume18
Issue number2
DOIs
StatePublished - Feb 24 2025

Bibliographical note

Publisher Copyright:
© BMJ Publishing Group Limited 2025.

Keywords

  • Autoimmunity
  • Immunology
  • Rheumatology

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Fingerprint

Dive into the research topics of 'Marked exacerbation of resolving macrophage activation syndrome in a patient with adult-onset Still's disease following one dose of granulocyte colony-stimulating factor'. Together they form a unique fingerprint.

Cite this